With AI Assistance in Colonoscopy, Benign Lesions More Often Removed
Colonoscopies assisted by AI technology are significantly more likely to result in the resection of benign lesions only.
Related Articles
Endoscopic sleeve gastroplasty ‘effective alternative’ for MASH, obesity management
Endoscopic sleeve gastroplasty with lifestyle intervention was more effective than lifestyle changes alone in achieving weight loss and histological improvement in patients with metabolic dysfunction-associated…
Hispanic patients with alcohol use disorder face greater odds for hepatitis, cirrhosis
Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according…
Management and outcomes of antithrombotic therapy in EUS-guided gallbladder drainage
EUS-guided gallbladder drainage (EUS-GBD) is increasingly used for the management of gallbladder disease in patients at high risk for cholecystectomy. These patients often have underlying…
ACG Virtual Grand Rounds | ACG
Participate in the ACG Virtual Grand Rounds. This educational series brings together gastroenterology and hepatology experts to share their insights and discuss topics.
Gender Inequity in Pharma-Supported Inflammatory Bowel Disease Presentations: Shining a Light on Opportunities for Equality and Transparency in Medical Research
Historically, women have been underrepresented in surgical and procedural disciplines,1 including gastroenterology (GI). Over the past 6 decades, the number of women in these disciplines…
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including…
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
TACE plus lenvatinib plus pembrolizumab showed significant, clinically meaningful improvement in progression-free survival in patients with unresectable, non-metastatic hepatocellular carcinoma compared with TACE plus placebo.…
Endoscopic vacuum therapy for the treatment of Boerhaave syndrome: a multicenter analysis
Boerhaave syndrome, an effort rupture of the esophagus, is a rare but serious condition. Endoscopic vacuum therapy (EVT) is a new therapeutic approach for GI…
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Immune checkpoint inhibitors (ICI) have led to breakthrough improvements in the management of malignancy including hepatocellular (HCC) and biliary tract cancer, improving decades-old standards of…
